Cepheid leverages automation and ease-of-use as core competitive advantages, reducing manual laboratory procedures and enabling decentralized testing. As a Danaher subsidiary since 2016, it benefits from parent company scale and resources while focusing on expanding its molecular diagnostics portfolio, including recent CE marking achievements for gastrointestinal pathogen detection panels.
Cyborg Score Rationale
Cepheid holds strong market position in molecular diagnostics with established GeneXpert platform and demonstrated product innovation. However, delisting status and subsidiary structure limit public visibility and independent financial transparency. Recent regulatory approvals suggest ongoing market expansion.
Top Insights
Cepheid received CE marking under IVDR in May 2026 for Xpert GI Panel, supporting detection of 11 gastrointestinal pathogens from single samples. Regulatory expansion enables European market entry and strengthens product portfolio competitiveness.
GeneXpert platform automates complex laboratory procedures with integrated analysis of biological samples in test cartridges, reducing operational complexity and enabling point-of-care deployment versus centralized facility infrastructure.
Danaher acquired Cepheid for $4 billion in 2016, integrating the company into its diagnostics portfolio. Subsidiary status since delisting provides Danaher direct control of molecular diagnostics strategy and revenue streams.
Named Competitors
Abbott Diagnostics — Molecular diagnostics and rapid testing systems
Qiagen — Molecular testing solutions and sample analysis platforms
BioMérieux — Clinical diagnostics and microbiology testing systems
Roche Diagnostics — Molecular diagnostics and automated laboratory testing systems
Hologic — Molecular diagnostics and laboratory-based testing analyzers
Siemens Healthineers — Molecular diagnostics and laboratory analyzer systems
Recent Developments
(May 2026) Received CE marking under IVDR for Xpert GI Panel for gastrointestinal pathogen detection
Open the full interactive Cepheid report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.